News
MedPage Today on MSN2d
Adding Menin Inhibitor Promising in Certain AML PatientsAdding the menin inhibitor revumenib (Revuforj) to azacitidine and venetoclax (Venclexta) seemed to benefit older adults with ...
Revumenib was generally well-tolerated in combination with venetoclax/azacitidine in older, newly diagnosed mNPM1 and KMT2Ar AML patients – – Promising clinical activity and deep responses observed ...
TipRanks on MSN2d
Syndax reports publication of revumenib data from BEAT AML trialPharmaceuticals announced that data from the BEAT AML trial of revumenib in combination with venetoclax and azacitidine in newly ...
To support physicians in treating cancer patients, oncology laboratories can benefit from adopting end-to-end automation of flow cytometry workflows. Rapid advances in automation are improving ...
Once submitted, we will try and place you in contact with a suitable Flow Cytometry Systems supplier within 48 hours.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback